Indoco Remedies Quarterly Results
Indoco Remedies quarterly results. In Sept 2026, Indoco Remedies (INDOCO) reported revenue ₹546 Cr and net profit ₹20 Cr — revenue +15.4% YoY. View INDOCO annual price range for the annual high/low range and current price position.
INDOCO Quarterly Results — Revenue, Profit & EPS Highlights
Indoco Remedies latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Also explore INDOCO share price charts to track price trends across different timeframes.
- Revenue of ₹546 Cr in Sept 2026 (+18.7% vs Mar 2026, +15.4% vs Sept 2025)
- Net Profit of ₹20 Cr in Sept 2026 (+183.3% vs Mar 2026, +322.2% vs Sept 2025)
- EBITDA of ₹72 Cr in Sept 2026 (+111.8% vs Mar 2026)
- Operating Margin of 7.0% in Sept 2026 (+0.0pp vs Mar 2026)
- Earnings Per Share of ₹2.11 in Sept 2026 (+182.1% vs Mar 2026)
Indoco Remedies Quarterly Results — Revenue, EBITDA, Net Profit & EPS
INDOCO quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Sept 2026 | Mar 2026 | Jun 2026 | Sept 2025 | Mar 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 546 | 460 | 566 | 473 | 386 | 18.7% | 15.4% |
| Net Profit (₹ Cr) | 20 | -24 | 65 | -9 | -41 | - | - |
| EBITDA (₹ Cr) | 72 | 34 | 139 | 30 | -5 | - | - |
| EPS (₹) | 2.11 | -2.57 | 7.09 | -1.00 | -4.48 | - | - |
| Operating Margin (%) | 7.0% | 7.0% | 9.0% | 6.0% | -2.0% | - | - |
INDOCO Share Price Trend — 1-Year Movement Across Quarterly Results
Indoco Remedies 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. For annual financials, live price and key ratios, visit INDOCO screener.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
INDOCO vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Indoco Remedies latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Sept 2026 |
₹451,074.97 Cr | 1900.0 | 16,617 | 1,995 | +10.6% | - | 12.0% | 228.9 |
|
Divis Laboratories
Sept 2026 |
₹294,139.19 Cr | 11178.0 | 3,770 | 1,127 | +26.3% | - | 29.9% | 263.1 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4611.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 400.6 |
|
Apollo Hospitals
Sept 2026 |
₹126,832.45 Cr | 8738.0 | 7,673 | 660 | +15.2% | - | 8.6% | 199.4 |
|
Laurus Labs
Sept 2026 |
₹125,946.78 Cr | 2306.0 | 2,219 | 436 | +21.7% | - | 19.6% | 282.3 |
QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores